What Does Sensei Biotherapeutics (SNSE) Do? — Complete Overview of Its Stock Outlook, Financials, Market Cap, Related Stocks, and Headquarters
A clinical-stage biotech developing differentiated immuno-oncology therapies, including VISTA checkpoint inhibitors, for cancer patients resistant to existing immunotherapies.
Subscribe🏢 What Kind of Company Is Sensei Biotherapeutics?
Sensei Biotherapeutics is a clinical-stage biotech developing next-generation immuno-oncology therapies that block the mechanisms cancer cells use to evade the immune system. Headquartered in Gaithersburg, Maryland, the company was founded in 2016. It is developing conditionally activated antibody technology based on its TMAb (Tumor Microenvironment Antibody) platform, which selectively activates antibodies within tumors.
💰 How Does It Make Money?
Sensei Biotherapeutics remains a research-and-development-focused company with no commercialized products and no current revenue. Clinical trial expenses are funded through proceeds from its existing initial public offering and additional capital raises.
| Pipeline | Target | Status |
|---|---|---|
| Solnerstotug (SNS-101) | VISTA checkpoint | Phase 1/2 solid tumor trials underway, including combination therapy with cemiplimab |
| SNS-102 | VSIG4 | Preclinical-stage target intended to suppress macrophages within tumors |
| SNS-103 | CD39 (ENTPDase1) | Preclinical-stage therapy designed to block the immunosuppressive adenosine pathway |
| PIKTOR | PI3K/AKT/mTOR | Under development for endometrial and breast cancers |
Its market capitalization is $17.4M, equivalent to approximately About 0% of Samsung Electronics' market cap. With 29 people employees, it is a small biotech that relies on capital raises to fund clinical trials. As a clinical-stage company, its valuation can vary significantly depending on trial outcomes.
📈 Sensei Biotherapeutics Outlook and Stock Performance
1-Year Price Performance
Analyst Consensus
52-Week Price RangeSensei's core value lies in its differentiated target, the VISTA checkpoint. Its strategy of targeting patients who do not respond to existing PD-1/PD-L1 immunotherapies is viewed positively in terms of market differentiation. At the 2025 ESMO Congress, the company presented sustained progression-free survival data in patients with PD-(L)1-resistant tumors, providing some evidence of clinical potential. However, as a clinical-stage biotech, its stock could plunge if trials fail, and commercialization will require substantial time and capital.
⚔️ Core Strengths and Risks
The company has differentiated immune-checkpoint technology, but it also carries the high level of uncertainty typical of clinical-stage biotech companies.
💪 Core Strengths
⚠️ Key Risks
Competitors and Related Stocks
Competitors: Merck is the global leader in the immuno-oncology market with Keytruda, while Bristol Myers Squibb competes with Opdivo. AstraZeneca has emerged as a formidable competitor in immuno-oncology through products such as Imfinzi.
Related stocks: Regeneron is a key partner and the developer of cemiplimab, which is being tested in combination with solnerstotug. Exelixis is a related company pursuing a similar strategy in immuno-oncology combination therapies, while Incyte is a small biotech focused on tumor immunology that shares broader industry trends with Sensei.
Check the real-time data for Sensei Biotherapeutics' competitors and related stocks in the table below.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| MRK | Merck & Co Inc | $143.93 | -0.5% | $355.1B | 115.0 | 8.5 | 6.98% | 2.37% |
| BMY | Bristol-Myers Squibb Co | $63.64 | -0.2% | $130.0B | 14.0 | 5.8 | 46.7% | 3.67% |
| AZN | Astrazeneca plc | $160.17 | +0.3% | $248.4B | 23.9 | 4.9 | 21.99% | 2.08% |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals Inc | $781.49 | -1.5% | $80.5B | 19.3 | 2.5 | 14.04% | 0.5% |
 EXEL | Exelixis Inc | $56.12 | -2.3% | $13.9B | 17.6 | 7.6 | 44.39% | - |
 INCY | Incyte Corp | $121.47 | -1.5% | $24.6B | 15.5 | 3.9 | 30.67% | - |
✅ Investor Checklist
Sensei Biotherapeutics is developing a new treatment option for patients who do not respond to existing immunotherapies. A successful trial outcome could lead to an acquisition or licensing agreement with a major pharmaceutical company, making it a high-risk, high-reward investment with substantial return potential.
| Checkpoint | What to Monitor | Current Status |
|---|---|---|
| 🔬 Clinical progress | Are clinical trials for the core pipeline progressing as expected? | ✅ Phase 1/2 trials underway |
| Cash position | Does the company have enough cash to cover clinical expenses? | Requires continued monitoring |
| 📊 Clinical data | Is the company reporting positive clinical results? | ✅ ESMO data presented |
| ⚡ Catalysts | Are future conference presentations or clinical data readouts scheduled? | ✅ Major conference presentations planned |
Clinical-stage biotech stocks can rise by dozens of percentage points following positive data, but disappointing results can also cause declines of more than 50% in a single day. Investors should strictly follow a diversification strategy and allocate only a small portion of their overall portfolio to such stocks.
In summary, Sensei Biotherapeutics is a promising biotech pursuing unmet medical needs through differentiated immune-checkpoint technology, but clinical uncertainty remains its principal risk. Investors should monitor clinical data presentation schedules regularly and approach the stock with a small position.
View Sensei Biotherapeutics' real-time price, technical indicators, and peer comparisons at a glance in US Stock Today's real-time dashboard.
Subscribe Today's 5 AI picks, all free